In a report released today, David Turkaly from JMP Securities maintained a Buy rating on AxoGen (AXGN – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $9.58. According to TipRanks.com, Turkaly is a 2-star analyst with an average return of 0.6% and a 42.3% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics. AxoGen has an analyst consensus of Strong Buy, with a price target consensus of $17.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $22.82 and a one-year low of $6.87.
https://www.tipranks.com/news/blurbs/jmp-securities-maintains-a-buy-rating-on-axogen-axgn?utm_source=advfn.com&utm_medium=referral
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Axogen Charts.
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Axogen Charts.